Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 3/20 | 0.34 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.31 |
| ▸ | PARP1 | P09874 | 2/20 | 0.31 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.30 |
| ▸ | ILK | Q13418 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30536586 | 1.00 | PDPK1 (0.36) | PDPK1JAK2IDO1MAP2K4TRPA1 | |
| SCHEMBL25340984 | 0.92 | PDPK1 (0.36) | PDPK1JAK2IDO1MAP2K4TRPA1 | |
| SCHEMBL30599435 | 0.81 | PDPK1 (0.34) | PDPK1JAK2IDO1MAP2K4 | |
| SCHEMBL11970930 | 0.81 | ADORA2A (0.47) | PDPK1JAK2IDO1MAP2K4ILK | |
| SCHEMBL17678215 | 0.81 | PDPK1 (0.34) | PDPK1JAK2IDO1MAP2K4 | |
| SCHEMBL25394513 | 0.81 | TRPA1 (0.35) | PDPK1JAK2IDO1MAP2K4TRPA1 | |
| SCHEMBL25394366 | 0.77 | NTRK1 (0.38) | PDPK1JAK2IDO1TRPA1 | |
| SCHEMBL30301459 | 0.77 | IDO1 (0.33) | PDPK1JAK2IDO1MAP2K4PARP1 | |
| SCHEMBL25367653 | 0.76 | ESR1 (0.36) | PDPK1JAK2MAP2K4TRPA1MAP2K7 | |
| SCHEMBL29493868 | 0.76 | ESR1 (0.36) | PDPK1JAK2MAP2K4TRPA1MAP2K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179028-A1 | ACRYLAMIDE COMPOUNDS | NRG THERAPEUTICS LTD (GB) | 2025-06-05 | — | — | US | disclosed |
| EP-4486721-A1 | ACRYLAMIDE COMPOUNDS | NRG Therapeutics LTD (GB) | 2025-01-08 | — | — | EP | disclosed |
| US-20240083853-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, INC. | 2024-03-14 | — | — | US | disclosed |
| WO-2023166303-A1 | ACRYLAMIDE COMPOUNDS | NRG THERAPEUTICS LTD (GB) | 2023-09-07 | — | — | WO | disclosed |
| CN-116600801-A | HSD17B13 inhibitors and uses thereof | FL2022-001公司 | 2023-08-15 | — | — | CN | disclosed |
| EP-4221701-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, Inc. (US) | 2023-08-09 | — | — | EP | disclosed |
| WO-2022072491-A1 | HSD17B13 INHIBITORS AND USES THEREOF | METACRINE, INC. (US) | 2022-04-07 | — | — | WO | disclosed |
| US-20210292305-A1 | Cyclic Ureas | SIRONAX LTD (KY) | 2021-09-23 | — | — | US | disclosed |
| CN-113302183-A | Cyclic ureas | 圣瑞诺有限公司 | 2021-08-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179028-A1 | ACRYLAMIDE COMPOUNDS | ACR, CCNI, FANCI | PDPK1 3904/4885JAK2 2138/4885IDO1 3619/4885 |
| US-20240083853-A1 | HSD17B13 INHIBITORS AND USES THEREOF | HSD17B3, HSD17B11, HSD17B1 | PDPK1 1978/4885JAK2 3555/4885IDO1 3953/4885 |
| US-20210292305-A1 | Cyclic Ureas | RIPK1, RIPK3, RIPK4 | PDPK1 983/4885JAK2 1432/4885IDO1 2091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.